199 related articles for article (PubMed ID: 35909547)
21. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
23. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.
Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA
Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576
[TBL] [Abstract][Full Text] [Related]
24. Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.
Miśkiewicz P; Jankowska A; Brodzińska K; Milczarek-Banach J; Ambroziak U
Int J Endocrinol; 2018; 2018():1978590. PubMed ID: 30420883
[TBL] [Abstract][Full Text] [Related]
25. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
Pramono LA
Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
[TBL] [Abstract][Full Text] [Related]
27. Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy.
Walasik-Szemplińska D; Kamiński G; Sudoł-Szopińska I
Thyroid Res; 2019; 12():13. PubMed ID: 31890036
[TBL] [Abstract][Full Text] [Related]
28. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
[No Abstract] [Full Text] [Related]
29. Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism.
Le Moli R; Malandrino P; Russo M; Lo Giudice F; Frasca F; Belfiore A; Vigneri R
Front Endocrinol (Lausanne); 2020; 11():367. PubMed ID: 32595602
[No Abstract] [Full Text] [Related]
30. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM;
Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684
[TBL] [Abstract][Full Text] [Related]
31. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
[TBL] [Abstract][Full Text] [Related]
32. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
[TBL] [Abstract][Full Text] [Related]
33. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis.
Florez H; Hernández-Rodríguez J; Muxi A; Carrasco JL; Prieto-González S; Cid MC; Espinosa G; Gómez-Puerta JA; Monegal A; Guañabens N; Peris P
Rheumatology (Oxford); 2020 Jul; 59(7):1574-1580. PubMed ID: 31628810
[TBL] [Abstract][Full Text] [Related]
34. Bone microarchitecture and bone mineral density in Graves' disease.
Boro H; Malhotra R; Kubihal S; Khatiwada S; Dogra V; Mannar V; Ahirwar AK; Rastogi V
Osteoporos Sarcopenia; 2023 Jun; 9(2):70-75. PubMed ID: 37496984
[TBL] [Abstract][Full Text] [Related]
35. Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position.
Krohn K; Schwartz EN; Chung YS; Lewiecki EM
J Clin Densitom; 2019; 22(4):501-505. PubMed ID: 31383412
[TBL] [Abstract][Full Text] [Related]
36. Trabecular Bone Score Reflects Trabecular Microarchitecture Deterioration and Fragility Fracture in Female Adult Patients Receiving Glucocorticoid Therapy: A Pre-Post Controlled Study.
Chuang MH; Chuang TL; Koo M; Wang YF
Biomed Res Int; 2017; 2017():4210217. PubMed ID: 28127556
[TBL] [Abstract][Full Text] [Related]
37. Effect of methylprednisolone pulse therapy with and without alendronate on biochemical markers of bone turnover in patients with Graves' ophthalmopathy.
Gasińska T; Borowska A; Wichary H; Dec R
Pol Arch Med Wewn; 2012; 122(7-8):341-7. PubMed ID: 22728519
[TBL] [Abstract][Full Text] [Related]
38. A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure.
Detiger SE; Kremer TM; A S H Dalm V; de Keizer ROB; Wubbels RJ; Metselaar JM; van Hagen PM; Peeters RP; Paridaens D
Acta Ophthalmol; 2021 Nov; 99(7):797-804. PubMed ID: 33423386
[TBL] [Abstract][Full Text] [Related]
39. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
